Proactive Investors - Run By Investors For Investors

Ellex Medical Lasers treatment receives German praise

Ellex Medical Lasers treatment receives German praise

Ellex Medical Lasers’ (ASX:ELX) proprietary Canaloplasty technology has been recognised as the new ‘gold standard’ in the surgical treatment of glaucoma by patient advocacy group The German Federate Eye Association.

This is a step towards the technology being recognised as the standard of care for glaucoma surgery worldwide.

The glaucoma surgical device market is valued at about A$275 million. This is expected to grow at an annual rate of 24% to reach $A$870 million by 2019.


Canaloplasty uses the company’s patented iTrack microcatheter to enlarge the eye’s natural drainage system.

Unlike traditional trabeculectomy surgery, which creates an artificial drainage channel, Canaloplasty restores the function of the eye’s natural outflow system in order to reduce the elevated intraocular pressure associated with glaucoma.

Being minimally invastive, Canaloplasty provides an improved safety profile and allows surgeons to reduce or eliminate many post-operative complications.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full ELX profile View Profile

Ellex Medical Lasers Timeline

November 30 2016

Related Articles

December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 06 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use